Cancer Supportive Care Products Market is Expected to Grow at a CAGR of 4.50% by the End of 2021

VALLEY COTTAGE, N.Y. – Rising prevalence of cancers and adverse effects cases during cancer treatment will remain the most prominent factor driving the demand for cancer supportive care products on a global level. FMI indicates steady growth prospects for the global cancer supportive care products market over 2016-2021. The market is likely to reach US$ 25.35 Bn in 2016. Erythropoietin stimulating agents will register the highest consumption. North America is expected to retain the largest market.

Growing prominence of cancers is anticipated to spur the demand for supportive care. In addition, rising incidences of side-effects of anti-cancer therapy and superior results of existing anti-cancer drugs will collectively propel consumption of cancer supportive care products globally. Awareness about the usage of supportive care in cancer treatment, especially in developing countries, will also be a key factor highlighting the growing popularity of cancer supportive care products. Government initiatives regarding improved healthcare infrastructure, rising R&D investments, and augmenting healthcare spending are identified to be the major factors positively impacting the market growth. Since the past few years, innovative drug development has been on the priority for leading manufacturers. This is predicted to be a booster to the demand for cancer supportive care products.

Download the sample copy of Report with table of contents and Figures @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2550

However, high costs and inadequate reimbursement policies will remain longstanding challenges to the market growth. Moreover, promising entry of biosimilar drugs and loss of generic drugs brand exclusivity may also detain the market post-2016.  

By drug class, the global cancer supportive care products market has eight key segments i.e.:

• non-steroidal anti-inflammatory drugs
• anti-infective
• anti-emetics
• monoclonal antibodies
• erythropoietin stimulating agents
• opioid analgesics
• bisphosphonates
• granulocyte colony stimulating factors

Erythropoietin stimulating agents segment will continue to dominate with over 24% value share in 2016. Granulocyte colony stimulating factors will however be the second largest segment with almost 20% market share by 2016 end.

Preview Analysis of Cancer Supportive Care Products Market: Lung Cancer Segment Projected to Remain Dominant over the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016-2021 – https://www.futuremarketinsights.com/reports/cancer-supportive-care-products-market

Based on disease indication, lung cancer will continue to dominate other segments, including:

• melanoma
• leukemia
• breast cancer
• liver cancer
• prostate cancer
• bladder cancer
• ovarian cancer

Breast cancer segment is likely to emerge at the highest growth rate. This growth is attributed to increasing cases of genetic inheritance, evolving lifestyle of women, and rising adoption of hormone replacement therapy.

On the basis of distribution channel, the market is classified into three key segments viz. hospital pharmacies, retail pharmacies, and compounding pharmacies.

By geography, North America will remain the key market with over 43% market value share, followed by Europe with around 20% share by 2016, in terms of revenues. However, APAC is expected to witness at the fastest growth rate, creating the most lucrative market.

Buy this report @ https://www.futuremarketinsights.com/checkout/2550

The key players participating in the global cancer supportive care products marketplace, include :

• Baxter International Inc
• Novartis Ag.
• Johnson & Johnson
• Amgen Inc.
• Hoffmann LA- Roche Ltd
• APR Applied Pharma Science Research S.A.
• Teva Pharmaceuticals Industries Ltd
• Fagron Group BV
• Acacia Pharma Ltd.
• Kyowa Hakko Kirin Co Ltd.

Long-term Outlook: Over 2016-2021, the global market for cancer supportive care products is poised to expand at a CAGR of around 4.5%, reaching a value of US$ 29.87 Bn by 2021 end.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-2550

More from Healthcare, Pharmaceuticals and Medical devices :

• Generic Injectable Market
• Phytopathological Disease Diagnostics Market
• Companion Animal Speciality Drugs Market

About us

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us
Mr. Abhishek Budholiya
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44-(0)-20-7692-8790 
Sales: sales@futuremarketinsights.com  
Press Office: Press@futuremarketinsights.com 
Website: https://www.futuremarketinsights.com/